Study on indicators for predicting the therapeutic effect of SGLT2 inhibitors under actual clinical practice in T2DM patients

Study on indicators for predicting the therapeutic effect of SGLT2 inhibitors under actual clinical practice in T2DM patients - Study on indicators for predicting therapeutic effect of SGLT2 inhibitors.

Status

Active, not recruiting

Phases

Phase 3

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000032848

Enrollment

100

Registered

2018-06-03

Start date

2018-02-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellituds

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Japanese T2DM patients who started SGLT2 inhibitor and received regular ambulatory treatment in Osaki Citizen Hospital Division of Endocrinology and Diabetes between May 2015 and April 2017

Exclusion criteria

Exclusion criteria: 1) Anti-glutamic acid decarboxylase (GAD) antibody above normal range. 2) HBs antigen or/end HCV antibody is positive. 3)Patients who discontinue the use of SGLT2 inhibitors during the period. 4)Patients who were taking acarbose and/or herbal medicines.

Design outcomes

Primary

Measure	Time frame
Improvement of HbA1c decrese of Body Weight	—

Secondary

Measure	Time frame
Improvement of liver function Improvement of fatty liver	—

Countries

Japan

Contacts

Public ContactMasahiro Usui

Osaki Citizen Hospital Division of Metabolism and Diabetes

masausui@med.tohoku.ac.jp0229-23-3311

Outcome results